Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature

Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Fuhrmann, Christian, Struck, Julian P., Ivanyi, Philipp, Kramer, Mario W., Hupe, Marie C., Hensen, Bennet, Fürschke, Alexander, Peters, Inga, Merseburger, Axel S., Kuczyk, Markus A., von Klot, Christoph-A. J.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7253725/
https://ncbi.nlm.nih.gov/pubmed/32528889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00808
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados